MAPT and neurodegenerative disease: In addition, the research did not perform high-throughput screening, but only tested for identified indicators of other neurodegenerative diseases (e.g., neurofilament light chain protein, total tau and phosphorylated tau-181), which have been found to be lack of specificity for CTE diagnosis.